Novartis Pharmaceuticals
NYSE NVS · Basel, Switzerland
Works in Cardiovascular · Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Psychiatry · Renal & urogenital · Respiratory · Women's health
Novartis Pharmaceuticals is a clinical trial sponsor based in Basel, Switzerland, listed as NYSE NVS. It has 364 active clinical trials with 215,238 planned participants, across 17 therapeutic areas. Since 2021 it has completed 714 trials and stopped 207 early. Its FDA record on file shows 1 inspection.
Trial track record · since 2021
FDA record
Recent FDA actions
Financials · NYSE NVS
Fundraising
Pipeline · 364 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
73 approved drug applications with a product on the market.
Questions about Novartis Pharmaceuticals
No warning letter naming Novartis Pharmaceuticals is on file. FDA has published 1 inspection classification naming it.
FDA has posted 1 inspection classification naming Novartis Pharmaceuticals. The latest inspection ended on 2026-06-24 and was classified NAI (no action indicated). FDA posts a classification after its review, often months after the inspection ended.
Novartis Pharmaceuticals is lead sponsor of 364 active clinical trials on ClinicalTrials.gov, with 215,238 planned participants, in Cardiovascular, Dermatology, ENT, Genetic & rare and other areas. Since 2021 it has completed 714 trials and stopped 207 early.
Novartis Pharmaceuticals is based in Basel, Switzerland and is listed as NYSE NVS. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Novartis Pharmaceuticals; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-16.
The FDA record counts inspection classifications, warning letters and recalls FDA has published that name this company. Compare it with the industry in the free CDMO FDA inspection lookup.
Approve Suite is not affiliated with Novartis Pharmaceuticals.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.